Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Verrica Pharmaceuticals (VRCA) Revenue (2021 - 2025)

Verrica Pharmaceuticals has reported Revenue over the past 5 years, most recently at $5.1 million for Q4 2025.

  • Quarterly results put Revenue at $5.1 million for Q4 2025, up 1380.23% from a year ago — trailing twelve months through Dec 2025 was $35.6 million (up 219.71% YoY), and the annual figure for FY2025 was $35.6 million, up 370.22%.
  • Revenue for Q4 2025 was $5.1 million at Verrica Pharmaceuticals, down from $14.3 million in the prior quarter.
  • Over the last five years, Revenue for VRCA hit a ceiling of $14.3 million in Q3 2025 and a floor of $37000.0 in Q1 2023.
  • Median Revenue over the past 5 years was $2.9 million (2023), compared with a mean of $4.3 million.
  • Biggest five-year swings in Revenue: tumbled 96.41% in 2022 and later skyrocketed 10240.54% in 2024.
  • Verrica Pharmaceuticals' Revenue stood at $12.0 million in 2021, then plummeted by 99.43% to $68000.0 in 2022, then skyrocketed by 2823.53% to $2.0 million in 2023, then plummeted by 82.7% to $344000.0 in 2024, then surged by 1380.23% to $5.1 million in 2025.
  • The last three reported values for Revenue were $5.1 million (Q4 2025), $14.3 million (Q3 2025), and $12.7 million (Q2 2025) per Business Quant data.